USE OF SUBSTITUTED 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE AND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO[1,2-a] PYRIMIDIN-5(1H)ONE DERIVATIVES AS THERAPEUTIC AGENTS

A method for the treatment of a disease selected from the group consisting of Alzheimer's disease, Parkinsons disease, taupathies, obesity, manic depressive illness and schizophrenia, which comprises administering to a patient in need of said treatment an effective amount of a compound of formula (I) or a salt thereof:

• wherein:
• X represents two hydrogen atoms, a sulfur atom, an oxygen atom or a C1-2 alkyl group and a hydrogen atom;
• Y represents a bond, an ethenylene group, an ethynylene group, an oxygen atom, a sulfur atom, a sulfonyl group, a sulfoxide group, a carbonyl group, a hydroxyiminomethylene group, a dioxolan group, a nitrogen atom being optionally substituted by a C1-6 alkyl group, a phenyl group or a benzyl group;
• or a methylene group optionally substituted by one or two groups chosen from a C1-6 alkyl group, a benzyl group, a hydroxyl group, a C1-4 alkoxy group, a C1-2 perhalogenated alkyl group, an amino group, an acetylamino group or a phenyl group;
• R1 represents a 2, 3 or 4-pyridine ring optionally substituted by a C3-6 cycloalkyl group, a C1-4 alkyl group, a C1-4 alkoxy group, a benzyl group or a halogen atom;
• when Y represents a bond, a methylene group optionally substituted, a hydroxyiminomethylene group, a dioxolan group or a carbonyl group then R2 represents a C1-6 alkyl group optionally substituted by a hydroxy group, a C6,10 aryloxy or a C6,10 arylamino group;
• a C3-6 cycloalkyl group, a C1-4 alkylthio group, a C1-4 alkoxy group, a C1-2 perhalogenated alkyl group, a C1-3 halogenated alkyl group, a phenylthio group, a benzyl group, a benzene ring, an indan ring, a 5,6,7,8-tetrahydronaphthalene ring, a naphthalene ring, a pyridine ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring;
• the benzyl group or the rings being optionally substituted by 1 to 4 substituents selected from a C1-6 alkyl group, a methylenedioxy group, a halogen atom, a C1-2 perhalogenated alkyl group, a C1-3 halogenated alkyl group, a hydroxyl group, a C1-4 alkoxy group, a nitro, a cyano, an amino, a C1-5 monoalkylamino group, a C2-10 dialkylamino group, a C1-6 alkylcarbonylamino group, a C6,10 arylcarbonylamino group, a C1-4 alkylsulfonyl group, C1-4 alkylsulfonyloxy group or a phenyl group;
• when Y represents a ethenylene group, a ethynylene group, an oxygen atom, a sulfur atom, a sulfonyl group, a sulfoxide group or a nitrogen atom being optionally substituted then R2 represents a C1-6 alkyl group optionally substituted by a hydroxy group, a C6,10 aryloxy or a C6,1o arylamino group;
• a C3-6 cycloalkyl group, a C1-2 perhalogenated alkyl group, a C1-3 halogenated alkyl group, a benzyl group, a benzene ring, an indan ring, a 5,6,7,8-tetrahydronaphthalene ring, a naphthalene ring, a C6, 10 arylamino, a pyridine ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring ;
• the benzyl group or the rings being optionally substituted by 1 to 4 substituents selected from a C1-6 alkyl group, a methylenedioxy group, a halogen atom, a C1-2 perhalogenated alkyl group, a C1-3 halogenated alkyl group, a hydroxyl group, a C1-4 alkoxy group, a nitro, a cyano, an amino, a C1-5 monoalkylamino group, a C2-10 dialkylamino group, a C1-6 alkylcarbonylamino group, a C6, 10 arylcarbonylamino group, a C1-4 alkylsulfonyl group, C1-4 alkylsulfonyloxy group or a phenyl group;
• R3 represents a hydrogen atom, a C1-6 alkyl group, a hydroxy group, a C1-4 alkoxy group or a halogen atom;
• R4 represents a hydrogen atom, a C1-6 alkyl group, a hydroxy group, a C1-4 alkoxy group or a halogen atom;
• R5 represents a hydrogen atom, a C1-6 alkyl group or a halogen atom;
• with the proviso that when R3 and R4 represent each a hydrogen atom then R5 is not a hydrogen atom;
• when m equals 0, p equals 1, 2 or 3,
• when m equals 1, p equals 0, 1 or 2,
• when m equals 2, p equals 0 or 1;
• and
• n represents 0 to 3.